VEMURAFENIB

Course overview

VEMURAFENIB IS FDA-APPROVED FOR METASTATIC AND UNRESPECTABLE MELANOMA WITH V600 MUTATION, AND ERDHEIM- CHESTER DISEASE (NON-LANGERHANS HISTIOCYTIC DISORDER). NON-FDA-LABELED INDICATIONS INCLUDE METASTATIC AND UNRESPECTABLE MELANOMA WITH BRAF V600K, AND REFRACTORY NON-SMALL CELL LUNG CARCINOMA BRAF V600 MUTATION. THIS ACTIVITY PROVIDES AN OVERVIEW OF THE INDICATIONS, MECHANISM OF ACTION, METHODS AND TIMING OF ADMINISTRATION, IMPORTANT ADVERSE EFFECTS, CONTRAINDICATIONS, TOXICITY, AND MONITORING FOR VEMURAFENIB AS CHEMOTHERAPY FOR INDICATED CANCERS.